IMU Biosciences closed an expanded Series A funding round totaling £40 million (about $53.9 million), adding £28.5 million to an earlier close in January 2024. The company says it has built a high-definition immune system dataset with near-term clinical applications in areas including transplant rejection and immuno-oncology. The financing is intended to support operational expansion, infrastructure growth, and further evolution of its clinical immune profiling platform. The company’s dataset claim—spanning almost 25,000 profiles of healthy volunteers plus disease cohorts—positions IMU for pharma collaborations that require consistent, deep immunophenotyping. For drug developers, high-dimensional immune profiling tools remain a bottleneck for reliable patient stratification, biomarker development, and mechanism-of-action validation; IMU’s funding underscores continuing demand for these capabilities.